Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status

Cancer Journal from Scientific American

Volumn 2, Issue 4, 1996, Pages 225-233

  Vijayakumar, Srinivasan ^a   Weichselbaum, Ralph ^a   Vaida, Florin ^a   Dale, William ^a   Hellman, Samuel ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Epidemiology; Prostate cancer; Prostate specific antigen; Race; Socioeconomic status

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CANCER STAGING; ECONOMICS; ETHNOLOGY; HUMAN; INSURANCE; MALE; NEGRO; PROSTATE TUMOR; SOCIOECONOMICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; HUMANS; INSURANCE COVERAGE; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 0000949859     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Bal DG. Guest editorial: cancer in African Americans. CA Cancer J 1992;42:5-6.
2. Wingo PA, Tong T, Bolden S. Cancer Statistics 1995. CA Cancer J 1995;45:8-30.
3. Dayal HH, Polissar L, Sahlberg S. Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst 1985; 74:1001-1006.
4. Guinan PD, Wiggishoff CC, Rotkin ID et al. Prostate cancer in Illinois. Ill Med J 1984;166:341-345.
5. Mebane C, Gibbs Y, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc 1990;82:782-783.
6. Natarajan N, Murphy GP, Mettlin C. Prostate cancer in blacks: an update from the American College of Surgeons' Patterns of Care Studies. J Surg Oncol 1989;40:232-236.
7. Mettlin CJ, Murphy G. The National Cancer Data Base Report on Prostate Cancer. Cancer 1994;74:1640-1648.
8. Council on Ethical and Judicial Affairs, American Medical Association: Black-White Disparities in Health Care. JAMA 1990;263: 2344-2346.
9. Ellis SJ. Effect of race on access and outcome in renal transplantation [letter]. N Engl J Med 1991;325:428-429.
10. Kasiske BL. Effect of race on access and outcome in renal transplantation [letter]. N Engl J Med 1991; 325:428-429.
11. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other disease among Japanese in the United States. J Nad Cancer Inst 1968; 40:43-68.
12. Staszwaski J, Haenszel W. Cancer mortality among the Polish born in the United States. J Natl Cancer Inst 1965; 35:291-297.
13. Waterhouse J, Muir CS, Correa P, Powell J (eds): Cancer Incidence in Five Continents. Vol. III. Lyon: IARC, 1976.
14. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer Prostate 1990; 16: 187-197.
15. Hill P, Wynder EL, Garbaczewski L et al. Diet and urinary steroids in black and white men and black South African men. Cancer Res 1979; 39:5101-5105.
16. Ross R, Bernstein E, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76:45-48.
17. Ross RK, Bernstein L, Lobo RA et al. Evidence for reduced 5-alpha-reductase activity in Japanese compared to U.S. Caucasian and African-American males: implications for prostate cancer risk. Lancet 1992; 339:887.
18. Andriole GL. Serum prostate-specific antigen: the most useful tumor marker. J Clin Oncol 1992; 10:1205-1207.
19. Gittes RF. Prostate-specific antigen. N Engl J Med 1987; 317: 954-955.
20. Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-1083.
21. Stamey TA, Yang N, Hay AR et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-915.
22. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidem Biomark Prevent 1992; 1:541-545.
23. Comer J, Mueller K. Correlates of health insurance coverage: evidence from the Midwest. J Health Care Poor Underserv, 1992; 3:305-320.
24. Swartz K, Marcotte J, McBride TD. Personal characteristics and spells without health insurance. Inquiry 1993; 30:64-76.
25. Pamies RJ, Woodard LJ. Cancer in socioeconomically disadvantaged populations. Primary Care, 1992; 19:443-450.
26. Freeman HE, Corey CR. Insurance status and access to health services among poor persons. Health Serv Res 1993;28:531-541.
27. Saver BG, Peterfreund N. Insurance, income, and access to ambulatory care in King County. Am J Pub Health 1993; 83:1583-1588.
28. Franks P, Clance CM. Health insurance and mortality. Evidence from a national cohort. JAMA 1993; 270:737-741.
29. Dale W, Vijayakumar S, Lawlor E, Merrell K. Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Prostate 1996; in press.
30. Littrup PJ, Kane RA, Williams CR et al. Determination of prostate volume with transrectal US for cancer screening. Part I. Comparison with prostate-specific antigen assays. Radiology 1991; 178:537-542.
31. Mettlin C, Littrup PJ, Kane RA et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994; 74:1615-1620.
32. Vijayakumar S, Karrison T, Quadri SF et al. Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy: an update. Onkologie 1994; 17:578-585.
33. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, Iowa: Iowa State University Press, 1980.
34. Oesterling JE, Chan DW, Epstein JI et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 1988; 139:766.
35. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152:1358-1368.
36. Lee F, Littrup PJ, Loft-Christensen L et al. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Cancer 1992; 70 [suppl]:211-220.
37. Babaian RJ, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990; 4:135.
38. Babaian RJ, Miyashita H, Evans RB et al. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol 1992; 147:837-840.
39. Veneziano S, Pavlica P, Querze R et al. Correlation between prostate-specific antigen and prostate volume, evaluation by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. Eur Urol 1990; 18:112.
40. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urol 1995; 45:476-483.
41. Kuban DA, El-Mahdi AM, Schellhammer PF. Pretreatment PSA as a predictor of long-term outcome in patients definitively irradiated for prostatic carcinoma. Intl J Radiat Oncol Biol Phys 1995; xx:xxx-xxx.
42. Langa KM, Sussman EJ. The effect of cost-containment policies on rates of coronary revascularization in California. N Engl J Med 1993;329:1784-1789.
43. Siu AL, Leibowitz A, Brook RH, Goldman NS, Lurie N, Newhouse JD. Use of the hospital in a randomized trial of prepaid care. JAMA 1988; 259:1343-1346.
44. Manning WG, Leibowitz A, Goldberg GA, Rogers WH, Newhouse JP. A controlled trial of the effect of a prepaid group practice on use of services. N Engl J Med 1984; 310:1505-1510.
45. McCord C, Freeman HP. Excess Mortality in Harlem. N Engl J Med 1990;322:173-177.
46. Physician Payment Review Commission. Monitoring Access of Medicare Beneficiaries. No. 93-2. Washington, DC: PPRC, 1993.
47. Physician Payment Review Commission. Monitoring Access of Medicare Beneficiaries. No. 94-2. Washington, DC: PPRC, 1993.
48. Powell IJ. Racial and ethnic factors related to prostate cancer. Basic and clinical aspects of prostate cancer. Abstracts of Am Acad Cancer Res Special Conference, Palm Springs, CA, Dec. 1994.
49. Schroeder SA. Rationing medical care: a comparative perspective. N Engl J Med 1994; 331:1089-1091.
50. Carr JA, Di Rocco A. Excess mortality in Hatlem. N Engl J Med 1990;322:1606.
51. Whittemore AS, Lele C, Friedman GD et al. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst, 1995; 87:354-360.
52. McNeal JE, Villers AA, Redwine EA, Freiha FS. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66:1225-1233.
53. Vijayakumar S, Chan T, Ray V et al. Guidelines for defining target volumes in radiation therapy of prostate cancer. Onkologie 1993; 16:389-406.
54. Moul JW, Sesterhenn IA, Connelly RR et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA, 1995; 274:1277-1281.
55. Lawlor E, Vijayakumar S, Merrell K, Dale W. A framework for modeling social factors in cancer effectiveness research. Center for Health Policy Studies Working Paper #8, 1994.
56. Teshima T, Hanlon AM, Hanks GE. Pretreatment prostate-specific antigen values in patients with prostate cancer: 1989 Patterns of Care Study Process Survey. Int J Radiat Oncol Biol Phys 1995; 33:809-814.
57. Asbell SO, Vijayakumar S. Racial differences in prostate specific antigen levels in patients with local-regional prostate cancer. Prostate 1996; in press.